Rifamycin-Resistant Mycobacterium tuberculosis in the Highly Active Antiretroviral Therapy Era: A Report of 3 Relapses with Acquired Rifampin Resistance following Alternate-Day Rifabutin and Boosted Protease Inhibitor Therapy

被引：31

作者：

Jenny-Avital, Elizabeth R. ^{[1
]}

Joseph, Kareen ^{[2
]}

机构：

[1] Jacobi Med Ctr, Adm Childrens Serv Clin, Bronx, NY 10461 USA

[2] Morrisania Chest Clin, New York City Dept Hlth & Mental Hygn, Bronx, NY USA

来源：

CLINICAL INFECTIOUS DISEASES | 2009年 / 48卷 / 10期

关键词：

VIRUS-ASSOCIATED TUBERCULOSIS; HIV-RELATED TUBERCULOSIS; NEW-YORK-CITY; PHARMACOKINETIC INTERACTION; MONORESISTANT TUBERCULOSIS; ANTITUBERCULOSIS DRUGS; INFECTED PATIENTS; RISK-FACTORS;

D O I：

10.1086/598336

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Rifamycin-resistant Mycobacterium tuberculosis infection (i.e., by a strain of M. tuberculosis that is only resistant to rifamycins) occurs disproportionately among patients infected with the human immunodeficiency virus (HIV) who have a low CD4 cell count. We observed 3 genetically confirmed cases of relapse with rifamycin-resistant M. tuberculosis infection following concurrent treatment with rifabutin (dosage, 150mg every other day) and a ritonavir-boosted HIV protease inhibitor during a prior episode of drug-susceptible tuberculosis. Higher doses of rifabutin and a ritonavir-boosted HIV protease inhibitor as treatment for tuberculosis should be studied further.

引用

页码：1471 / 1474

页数：4

共 21 条

[1]

*ABB LAB, 2006, KAL LOP RIT PACK INS

[2]

[Anonymous], 2008, Guidelines for the use of antirretriviral agents in HIV-1 infected adults and adolescents

[3]

BOULANGER C, 2007, 4 INT AIDS SOC C HIV

[4] The changing epidemiology of acquired drug-resistant tuberculosis in San Francisco, USA [J].

Bradford, WZ ;

Martin, JN ;

Reingold, AL ;

Schecter, GF ;

Hopewell, PC ;

Small, PM .

LANCET, 1996, 348 (9032) :928-931

[5] Acquired rifamycin resistance with twice-weekly treatment of HIV-related tuberculosis [J].

Burman, W ;

Benator, D ;

Vernon, A ;

Khan, A ;

Jones, B ;

Silva, C ;

Lahart, C ;

Weis, S ;

King, B ;

Mangura, B ;

Weiner, M ;

El-Sadr, W .

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2006, 173 (03) :350-356

[6]

Centers for Disease Control and Prevention, MAN DRUG INT TREATM

[7] Pharmacokinetic interaction between fosamprenavir-ritonavir and rifabutin in healthy subjects [J].

Ford, Susan L. ;

Chen, Ya-Chi ;

Lou, Yu ;

Borland, Julie ;

Min, Sherene S. ;

Yuen, Geoffrey J. ;

Shelton, Mark J. .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2008, 52 (02) :534-538

[8] Decreased bioavailability of rifampin and other antituberculosis drugs in patients with advanced human immunodeficiency virus disease [J].

Gurumurthy, P ;

Ramachandran, G ;

Kumar, AKH ;

Rajasekaran, S ;

Padmapriyadarsini, C ;

Swaminathan, S ;

Bhagavathy, S ;

Venkatesan, P ;

Sekar, L ;

Mahilmaran, A ;

Ravichandran, N ;

Paramesh, P .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2004, 48 (11) :4473-4475

[9] Malabsorption of rifampin and isoniazid in HIV-infected patients with and without tuberculosis [J].

Gurumurthy, P ;

Ramachandran, G ;

Kumar, AKH ;

Rajasekaran, S ;

Padmapriyadarsini, C ;

Swaminathan, S ;

Venkatesan, P ;

Sekar, L ;

Kumar, S ;

Krishnarajasekhar, OR ;

Paramesh, P .

CLINICAL INFECTIOUS DISEASES, 2004, 38 (02) :280-283

[10] Steady-state pharmacokinetic interaction of modified-dose indinavir and rifabutin [J].

Hamzeh, FM ;

Benson, C ;

Gerber, J ;

Currier, J ;

McCrea, J ;

Deutsch, P ;

Ruan, P ;

Wu, HL ;

Lee, J ;

Flexner, C .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2003, 73 (03) :159-169

← 1 2 3 →